Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and cell-culture mechanistic study with a correlational human biomarker observation.
PubMed 27979832 · doi:10.1158/2159-8290.CD-16-0241
What was done
Researchers tested the effects of chemotherapeutic agents on primary murine and human cell senescence. Using a transgenic mouse model capable of tracking and clearing senolytic/senescent cells, they evaluated the role of therapy-induced senescent (TIS) cells in inflammation, bone marrow suppression, cardiac dysfunction, physical performance, and cancer relapse. They also assessed the relationship between baseline T-cell senescence marker expression and chemotherapy-induced fatigue in human patients.
What was found
Chemotherapy induced persistent senescent cells in primary murine and human cells, driving local and systemic inflammation in mice. Clearing TIS cells in mice reduced short- and long-term toxicities (bone marrow suppression, cardiac dysfunction, and impaired physical activity/strength) and lowered cancer recurrence. In humans, higher pre-chemotherapy T-cell senescence marker expression was associated with a significantly greater risk of chemotherapy-induced fatigue. The abstract reports no numerical values, effect sizes, or sample sizes.
Why it matters
It identifies therapy-induced cellular senescence as a driver of both acute and chronic chemotherapy toxicities and cancer recurrence, suggesting senescent cell clearance as a potential therapeutic strategy to reduce chemotherapy side effects.
Limits
The findings are primarily derived from preclinical mouse models and in vitro assays. The human analysis is correlational and the abstract provides no quantitative data, sample sizes, cohort characteristics, or specific chemotherapy regimens.
Cited by
- supports Genotoxic chemotherapies induce cellular senescence in transgenic mice, and eliminating those senescent cells eliminates several side effects of chemotherapy.